Aclaris Therapeutics Inc (NASDAQ:ACRS) price on Wednesday, November 13, fall -4.69% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $2.44.
A look at the stock’s price movement, the close in the last trading session was $2.56, moving within a range at $2.43 and $2.72. The beta value (5-Year monthly) was 0.116. Turning to its 52-week performance, $2.68 and $0.59 were the 52-week high and 52-week low respectively. Overall, ACRS moved 106.78% over the past month.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Aclaris Therapeutics Inc’s market cap currently stands at around $174.29 million, with investors looking forward to this quarter’s earnings report slated for in December.
Analysts have a consensus estimate of 2.12M for the company’s revenue for the quarter, with a low and high estimate of 650k and 4.4M respectively. The average forecast suggests down to a -87.90% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 10.79M, representing a -65.50% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that ACRS is a 100% Buy. On the other hand, the stock is on average a 100% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Buy category.
4 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 3 recommend ACRS as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 1 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
ACRS’s current price about 30.24% and 68.00% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 76.82, while 7-day volatility ratio is 14.27% and 10.50% in the 30-day chart. Further, Aclaris Therapeutics Inc (ACRS) has a beta value of 0.21, and an average true range (ATR) of 0.19. Analysts have given the company’s stock an average 52-week price target of $14, forecast between a low of $3 and high of $25. Looking at the price targets, the low is -22.95% off current price level while to achieve the yearly target high, price needs to move -924.59%. Nonetheless, investors will most likely welcome a -473.77% jump to $14 which is the analysts’ median price.
If we refocus on Aclaris Therapeutics Inc (NASDAQ:ACRS), historical trading data shows that trading volumes averaged 1.07 over the past 10 days and 531.02K over the past 3 months. The company’s latest data on shares outstanding shows there are 70.89 million shares.
The 5.41% of Aclaris Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 73.05% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 2.41 million on 2024-10-31, giving us a short ratio of 3.56. The data shows that as of 2024-10-31 short interest in Aclaris Therapeutics Inc (ACRS) stood at 403.0 of shares outstanding, with shares short rising to 1.73 million registered in 2024-09-30. Current price change has pushed the stock 132.38% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the ACRS stock continues to rise going into the next quarter.
